| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695377 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Based on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
John K. Chan, Wei Deng, Robert V. Higgins, Krishnansu S. Tewari, Albert J. Bonebrake, Michael Hicks, Stephanie Gaillard, Pedro T. Ramirez, Weldon Chafe, Bradley J. Monk, Carol Aghajanian,